S
Sylvia Richey
Researcher at University of Tennessee Health Science Center
Publications - 5
Citations - 2413
Sylvia Richey is an academic researcher from University of Tennessee Health Science Center. The author has contributed to research in topics: Prostate cancer & Androgen deprivation therapy. The author has an hindex of 5, co-authored 5 publications receiving 1787 citations. Previous affiliations of Sylvia Richey include Ohio State University.
Papers
More filters
Journal ArticleDOI
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
James L. Mohler,Emmanuel S. Antonarakis,Andrew J. Armstrong,Anthony V. D'Amico,Brian J. Davis,Tanya B. Dorff,James A. Eastham,Charles Arthur Enke,Thomas A. Farrington,Celestia S. Higano,Eric M. Horwitz,Michael E. Hurwitz,Joseph E. Ippolito,Christopher J. Kane,Michael Kuettel,Joshua M. Lang,Jesse K. McKenney,George J. Netto,David F. Penson,Elizabeth R. Plimack,Julio M. Pow-Sang,Thomas J. Pugh,Sylvia Richey,Mack Roach,Stan Rosenfeld,Edward M. Schaeffer,Ahmad Shabsigh,Eric J. Small,Daniel E. Spratt,Sandy Srinivas,Jonathan D. Tward,Dorothy A. Shead,Deborah A. Freedman-Cass +32 more
TL;DR: The NCCN Guidelines for Prostate Cancer include recommendations regarding diagnosis, risk stratification and workup, treatment options for localized disease, and management of recurrent and advanced disease for clinicians who treat patients with prostate cancer.
Journal ArticleDOI
Prostate Cancer, Version 1.2016
James L. Mohler,Andrew J. Armstrong,Robert R. Bahnson,Anthony V. D'Amico,Brian J. Davis,James A. Eastham,Charles Arthur Enke,Thomas A. Farrington,Celestia S. Higano,Eric M. Horwitz,Michael E. Hurwitz,Christopher J. Kane,Mark H. Kawachi,Michael Kuettel,Richard T. Lee,Joshua J. Meeks,David F. Penson,Elizabeth R. Plimack,Julio M. Pow-Sang,David Raben,Sylvia Richey,Mack Roach,Stan Rosenfeld,Edward M. Schaeffer,Ted A. Skolarus,Eric J. Small,Guru Sonpavde,Sandy Srinivas,Seth A. Strope,Jonathan D. Tward,Dorothy A. Shead,Deborah A. Freedman-Cass +31 more
TL;DR: This article summarizes the NCCN Prostate Cancer Panel's most significant discussions for the 2016 update of the guidelines, which include refinement of risk stratification methods and new options for the treatment of men with high-risk and very-high-risk disease and progressive castration-naïve disease.
Journal ArticleDOI
Prostate Cancer,,Version 2.2014 Clinical Practice Guidelines in Oncology
James L. Mohler,Philip W. Kantoff,Andrew J. Armstrong,Robert R. Bahnson,Michael B. Cohen,Anthony V. D'Amico,James A. Eastham,Charles Arthur Enke,Thomas A. Farrington,Celestia S. Higano,Eric M. Horwitz,Christopher J. Kane,Mark H. Kawachi,Michael Kuettel,Timothy M. Kuzel,Richard T. Lee,Arnold W. Malcolm,David Miller,Elizabeth R. Plimack,Julio M. Pow-Sang,David Raben,Sylvia Richey,Mack Roach,Eric M. Rohren,Stan Rosenfeld,Edward M. Schaeffer,Eric J. Small,Guru Sonpavde,Sandy Srinivas,Cy A. Stein,Seth A. Strope,Jonathan D. Tward,Dorothy A. Shead,Maria Ho +33 more
TL;DR: Significant updates for early disease include distinction between active surveillance and observation, a new section on principles of imaging, and revisions to radiation recommendations.
Journal ArticleDOI
Prostate cancer, version 1.2021: Featured updates to the nccn guidelines
Edward M. Schaeffer,Sandy Srinivas,Emmanuel S. Antonarakis,Andrew J. Armstrong,Justin E. Bekelman,Heather H. Cheng,Anthony V. D'Amico,Brian J. Davis,Neil Desai,Tanya B. Dorff,James A. Eastham,Thomas A. Farrington,Xin Gao,Eric M. Horwitz,Joseph E. Ippolito,Michael Kuettel,Joshua M. Lang,Rana R. McKay,Jesse K. McKenney,George J. Netto,David F. Penson,Julio M. Pow-Sang,Robert E. Reiter,Sylvia Richey,Mack Roach,Stan Rosenfeld,Ahmad Shabsigh,Daniel E. Spratt,Benjamin A. Teply,Jonathan D. Tward,Dorothy A. Shead,Deborah A. Freedman-Cass +31 more
TL;DR: The NCCN Guidelines for Prostate Cancer address staging and risk assessment after a prostate cancer diagnosis and include management options for localized, regional, and metastatic disease Recommendations for disease monitoring and treatment of recurrent disease are also included as mentioned in this paper.
Journal ArticleDOI
Prostate cancer, version 1.2014: Featured updates to the NCCN Guidelines
James L. Mohler,Philip W. Kantoff,Andrew J. Armstrong,Robert R. Bahnson,Michael B. Cohen,Anthony V. D'Amico,James A. Eastham,Charles Arthur Enke,Thomas A. Farrington,Celestia S. Higano,Eric M. Horwitz,Mark H. Kawachi,Michael Kuettel,Richard T. Lee,Gary R. MacVicar,Arnold W. Malcolm,David Miller,Elizabeth R. Plimack,Julio M. Pow-Sang,Sylvia Richey,Mack Roach,Eric M. Rohren,Stan Rosenfeld,Eric J. Small,Sandy Srinivas,Cy A. Stein,Seth A. Strope,Jonathan D. Tward,Patrick C. Walsh,Dorothy A. Shead,Maria Ho +30 more
TL;DR: The NCCN Prostate Cancer Panel revised recommendations on the choice of intermittent or continuous androgen deprivation therapy based on recent phase III clinical data comparing the 2 strategies in the nonmetastatic and metastatic settings.